Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study

References

• World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. 2013 [http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/]
   Google Scholar
• Global Alliance for Vaccines and Immunization (GAVI): Advance Market Commitments for Vaccines Update: World's Poorest Children Among First to Receive New Life-Saving Pneumococcal Vaccines. 2010; [http://www.vaccineamc.org/updatemar23_10.html]
   Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance LF, Reithinger R, Muenz LR, O'Brien KL. Systemic evaluation of serotypes causing invasive pneumococcal disease among children under five: the global serotype project. PLoS Med 2010, 7(10); PMID:20957191; http://dx.doi.org/10.1371/journal.pmed.1000348
   PubMed Web of Science ®Google Scholar
• Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Pediatr Infect Dis J 2004; 23(7):642-49; PMID:15247603; http://dx.doi.org/10.1097/01.inf.0000130951.85974.79
   PubMed Web of Science ®Google Scholar
• Collard JM, Alio Sanda AK, Jusot JF: Determination of pneumococcal serotypes in meningitis cases in Niger, 2001-2011. PLoS One 2013; 8(3):e60432; PMID:23555971; http://dx.doi.org/10.1371/journal.pone.0060432
   PubMedGoogle Scholar
• World Health Organization (WHO): Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007; 82:93-104; PMID:17380597
   PubMedGoogle Scholar
• Lagos RM, Muñoz AE, Levine MM, Lepetic A, François N, Yarzabal JP, Schuerman L. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 2011; 7(5):511-22; PMID:21441782; http://dx.doi.org/10.4161/hv.7.5.14634
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, Fanic A, Schuerman L. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 2011; 30(8):e130-41; PMID:21540760; http://dx.doi.org/10.1097/INF.0b013e31821d1790
   PubMed Web of Science ®Google Scholar
• Sartori AM, de Soárez PC, Novaes HM. Cost-effectiveness of introducing the 10- valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Community Health 2012; 66(3):210-17; PMID:20884668; http://dx.doi.org/10.1136/jech.2010.111880
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, Borys D, Goldblatt D, Scott JA. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. Plos One 2014; 9(1):e85459; PMID:24465570; http://dx.doi.org/10.1371/journal.pone.0085459
   PubMed Web of Science ®Google Scholar
• Odusanya OO, Kuyinu YA, Kehinde OA, Shafi F, François N, Yarzabal JP, Dobbelaere K, Rüggeberg JU, Borys D, Schuerman L. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life. Hum Vaccines Immunother 2013; 10(3):7-16
   Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Lommel P, Hezareh M, Moreira M, Schuerman L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381(9862):214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6
   PubMed Web of Science ®Google Scholar
• Kilpi T, Palmu AA, Puumalaien T, Nieminen H, Ruokokoski E, Moreira M, Hezareh M, Borys D, Schuerman L, Jokinen J. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHID-CV10) against hospital-diagnosed pneumonia in infants- FinIP trial. Abstract Presented at the 31st Meeting of the European Society for Paediatric Infectious Diseases 2013 May 28 - June 1; Milan, Italy.
   Google Scholar
• Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, François N, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 2011; 11:882-93; PMID:22112189; http://dx.doi.org/10.1186/1471-2458-11-882
   PubMed Web of Science ®Google Scholar
• Dicko A, Santara G, Mahamar A, Sidibe Y, Barry A, Dicko Y, Diallo A, Dolo A, Doumbo O, Shafi F, et al. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccin Immunother 2013; 9:382-88; PMID:23291945; http://dx.doi.org/10.4161/hv.22692
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009; 28(4 Suppl):S77-88; PMID:19325450; http://dx.doi.org/10.1097/INF.0b013e318199f609
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, Schuerman L. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae PD conjugate vaccine. Pediatr Infect Dis J 2009; 28(10):e276-82; PMID:20118683; http://dx.doi.org/10.1097/INF.0b013e3181b48ca3
   PubMedGoogle Scholar
• Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine co-administered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J 2010; 29(6):e47-56; PMID:20508478; http://dx.doi.org/10.1097/INF.0b013e3181dffabf
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chambre syringe to infants in Belgium and Chile. Vaccine 1998, 16(9-10):921-27; PMID:9682338; http://dx.doi.org/10.1016/S0264-410X(97)00303-4
   PubMed Web of Science ®Google Scholar
• Lagos R, Hoffenbach A, Scemama M, Dupuy M, Schodel F, Hessel L, Levine M. Lot-to-lot consistency of a combined hexavalent diphtheria-tetanus-acellular-pertussis, hepatitis B, inactivated polio and Haemophilus B conjugate vaccine, administered to healthy Chilean infants at two, four and six months of age. Hum Vaccin 2005; 1(3):112-17; PMID:17012870; http://dx.doi.org/10.4161/hv.1.3.1848
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, Aberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009; 28(4):S89-96; PMID:19325451; http://dx.doi.org/10.1097/INF.0b013e318199f901
   PubMedGoogle Scholar
• Park DE, Johnson TS, Nonyane BA, Chandir S, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL, et al. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity: Pediatr Infect Dis J 2014; 33 Suppl 18;2:S130-9; PMID:24336055; http://dx.doi.org/10.1097/INF.0000000000000081
   PubMedGoogle Scholar
• Nunes MC, Madhi SA. Review of the immunogenicity and safety of the PCV-13 in infants and toddlers. Expert Rev Vaccines 2011; 10(7):951-80; PMID:21806394; http://dx.doi.org/10.1586/erv.11.76
   PubMed Web of Science ®Google Scholar
• Borys D, Vesikari T, Tregnaghi MW, Sáez-Llorens X, Iwata S, Lommel P, Moreira M, Ruiz Guiñazú J. Population variability of the immune response following primary vaccination with the 10-valent pneumococcol non-typeable Haemophilus Influenzae protein D-conjugate vaccine (PHID-CV). Abstract presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases, 2014 Mar 9-13; Hyderabad, India.
   Google Scholar
• Concepcion N, Frasch C. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206
   PubMedGoogle Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13(3):356-60; PMID:16522777; http://dx.doi.org/10.1128/CVI.13.3.356-360.2006
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Kaythy H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940; http://dx.doi.org/10.1128/CVI.00289-09
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4(4):415-22; PMID:9220157
   PubMedGoogle Scholar